Loading...
Market
Story
FDA Approves Eli Lilly's EBGLYSS™ Eczema Drug for Adults and Children on Friday
Sep 13, 2024, 11:10 PM
Eli Lilly announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its eczema drug, EBGLYSS™ (lebrikizumab-lbkz), for use in adults and children aged 12 years and older. The drug is intended to treat moderate-to-severe atopic dermatitis, a condition characterized by itchy, dry, and scaly skin. This approval marks a significant advancement for individuals suffering from eczema, offering a new treatment option for a diverse group of patients.
View original story
Similar markets
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0-5 • 25%
6-10 • 25%
11-15 • 25%
16 or more • 25%
None • 25%
1 to 2 • 25%
3 to 4 • 25%
More than 4 • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
0 new indications • 33%
1 new indication • 33%
2 or more new indications • 34%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 5 new treatments • 25%